NKTX Nkarta, Inc.
USHealthcareAs of 2026-07-09 10:03
Why NKTX matters now
Nkarta, Inc. (NKTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.62 with -1.50% on the session and $258.6M in market capitalization; recent performance reads 1-month +6.72% and YTD +54.59%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-27.8M, and EPS of $-0.37. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -43.2%.
The latest indexable market news headline is "Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $9.00; recent insider activity includes Thedinga Angela filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.74
P/S
0.00
EV/EBITDA
-2.78
DCF Value
$-0.50
FCF Yield
-43.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-30.9%
ROA
-26.9%
ROIC
-32.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-27.8M | $-0.37 |
| Q4 2025 | $0.00 | $-27.4M | $-0.37 |
| FY 2025 | $0.00 | $-104.1M | $-1.41 |
| Q3 2025 | $0.00 | $-21.7M | $-0.29 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$9.00
Target (Median)
$9.00
Target Range
$9.00 - $9.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.90
Nkarta, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to advancing and marketing cell-based treatments for cancer. Their innovative cellular immunotherapy strategy outfits natural killer (NK) cells with chimeric antigen receptors (CARs) on their surface, allowing these cells to pinpoint particular proteins or antigens found on the exterior of tumor cells. The company's primary investigational products include NKX101, which is undergoing Phase I human trials for resistant or recurring acute myeloid leukemia and high-risk myelodysplastic syndromes. Another key candidate is NKX019, a pre-clinical asset designed to combat various B-cell malignancies by targeting the CD19 antigen present on these cancerous cells. Furthermore, Nkarta maintains a collaborative research partnership with CRISPR Therapeutics AG. Founded in 2015, the company's main operations are situated in South San Francisco, California.